Definium Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Definium completed a public offering of 23.7M shares generating $805M gross proceeds ($758M net), increasing cash to $1.1B as of June 30, 2026. Phase 3 Emerge study of DT120 ODT in major depressive disorder met primary endpoint with 8.1-point MADRS improvement over placebo (p<0.0001, Cohen's d=0.83); two Phase 3 GAD studies (Voyage, Panorama) completed enrollment with topline data expected August–September 2026. Q2 2026 net loss was $159M, driven primarily by $86.2M non-cash warrant liability revaluation; R&D spending increased 63% YoY to $48.7M.
Why this rating
Positive pivotal efficacy data and massive capital raise ($805M = 165% of market cap) materially strengthen near-term runway and commercial prospects; however, regulatory/clinical execution risk remains high.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.